Optimer's Fidaxomicin Among Three NMEs Given Positive Review By Europe's Regulators
This article was originally published in The Pink Sheet Daily
Executive Summary
EU's scientific advisory panel also recommends approval for Takeda's azilsartan and Tibotec's rilpivirine, and grants positive opinions on new indications for Bayer/Johnson & Johnson's rivaroxaban and Alexion's eculizumab.